​

Humacyte (HUMA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

HUMA Stock Forecast

Humacyte (HUMA) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $3.00, with a high of $3.00 and a low of $3.00. This represents a 270.37% increase from the last price of $0.81.

- $2 $4 $6 $8 $10 High: $3 Avg: $3 Low: $3 Last Closed Price: $0.81

HUMA Stock Rating

Humacyte stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (90.91%), 1 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 10 Strong Sell Sell Hold Buy Strong Buy

HUMA Price Target Upside V Benchmarks

TypeNameUpside
StockHumacyte270.37%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$4.17
Last Closing Price$0.81$0.81$0.81
Upside/Downside--414.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26151--7
Mar, 26151--7
Feb, 26151--7
Jan, 26151--7
Dec, 25151--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 01, 2025Swayampakula RamakanthH.C. Wainwright$3.00$1.35122.22%270.37%
Oct 13, 2025UBS$6.00$1.68257.14%640.74%
Aug 27, 2025Matt MiksicBarclays$3.50$1.47138.10%332.10%
Oct 18, 2024Matt O'BrienPiper Sandler$6.00$4.8623.46%640.74%
Oct 18, 2024Ryan ZimmermanBTIG$10.00$4.86105.76%1134.57%
Dec 20, 2022Cowen CowenCowen & Co.$5.00$2.21126.24%517.28%
May 15, 2022Matt O'BrienPiper Sandler$4.00$5.37-25.51%393.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 09, 2026BTIGBuyBuyhold
Jan 21, 2026BenchmarkBuyBuyhold
Dec 01, 2025UBSBuyBuyhold
Aug 27, 2025BarclaysOverweightinitialise
Nov 05, 2024H.C. WainwrightBuyBuyhold
Oct 18, 2024Cowen & Co.BuyBuyhold
Oct 18, 2024Piper SandlerNeutralNeutralhold
Oct 18, 2024BTIGBuyBuyhold
Sep 09, 2024EF HuttonBuyinitialise
Sep 05, 2024BenchmarkBuyBuyhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.66$-0.12$-1.07$-1.26$-0.26---
Avg Forecast$-1.55$-0.41$-1.05$-1.35$-0.86$-0.21$0.54$1.68
High Forecast$-0.80$-0.08$-1.04$-1.05$-0.80$1.20$2.98$3.33
Low Forecast$-3.37$-0.92$-1.07$-1.49$-0.99$-0.76$-0.43$0.41
Surprise %-57.42%-70.73%1.90%-6.67%-69.77%---

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.26M$1.56M--$2.04M---
Avg Forecast$1.22M$1.77M$50.00K$214.29K$9.53M$118.34M$270.38M$503.61M
High Forecast$2.34M$3.46M$87.74K$376.03K$14.17M$118.34M$270.38M$883.73M
Low Forecast$766.74K$666.66K$21.01K$90.04K$4.88M$118.34M$270.38M$211.62M
Surprise %3.16%-11.47%---78.62%---

Net Income Forecast

$-350M $-210M $-70M $70M $210M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-26.48M$-11.96M$-110.78M$-148.70M$-40.83M---
Avg Forecast$-160.03M$-42.40M$-109.26M$-152.87M$-92.62M$-24.81M$120.10M$173.75M
High Forecast$-82.28M$-8.07M$-107.75M$-108.95M$-82.92M$124.10M$308.19M$344.23M
Low Forecast$-348.93M$-95.14M$-110.77M$-154.07M$-102.31M$-78.60M$-44.47M$42.79M
Surprise %-83.46%-71.78%1.39%-2.73%-55.91%---

HUMA Forecast FAQ

Is Humacyte stock a buy?

Humacyte stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Humacyte is a favorable investment for most analysts.

What is Humacyte's price target?

Humacyte's price target, set by 11 Wall Street analysts, averages $3 over the next 12 months. The price target range spans from $3 at the low end to $3 at the high end, suggesting a potential 270.37% change from the previous closing price of $0.81.

How does Humacyte stock forecast compare to its benchmarks?

Humacyte's stock forecast shows a 270.37% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Humacyte over the past three months?

  • April 2026: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Humacyte’s EPS forecast?

Humacyte's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.21, marking a -19.23% decrease from the reported $-0.26 in 2025. Estimates for the following years are $0.54 in 2027, and $1.68 in 2028.

What is Humacyte’s revenue forecast?

Humacyte's average annual revenue forecast for its fiscal year ending in December 2026 is $118.34M, reflecting a 5706.47% increase from the reported $2.04M in 2025. The forecast for 2027 is $270.38M, and $503.61M for 2028.

What is Humacyte’s net income forecast?

Humacyte's net income forecast for the fiscal year ending in December 2026 stands at $-24.806M, representing a -39.25% decrease from the reported $-40.833M in 2025. Projections indicate $120.1M in 2027, and $173.75M in 2028.